JNJ

239.13

+0.39%↑

UNH

272.01

-0.45%↓

TMO

538.23

-4.32%↓

ABT

109.59

+0.95%↑

ISRG

486.71

+1.01%↑

JNJ

239.13

+0.39%↑

UNH

272.01

-0.45%↓

TMO

538.23

-4.32%↓

ABT

109.59

+0.95%↑

ISRG

486.71

+1.01%↑

JNJ

239.13

+0.39%↑

UNH

272.01

-0.45%↓

TMO

538.23

-4.32%↓

ABT

109.59

+0.95%↑

ISRG

486.71

+1.01%↑

JNJ

239.13

+0.39%↑

UNH

272.01

-0.45%↓

TMO

538.23

-4.32%↓

ABT

109.59

+0.95%↑

ISRG

486.71

+1.01%↑

JNJ

239.13

+0.39%↑

UNH

272.01

-0.45%↓

TMO

538.23

-4.32%↓

ABT

109.59

+0.95%↑

ISRG

486.71

+1.01%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

50%

147 / 352 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. veebr 2026, 23:57 UTC

Tulu

Naver Has Record Year Despite Weaker Final Quarter

5. veebr 2026, 23:45 UTC

Kuumad aktsiad

Stocks to Watch: Amazon, Coty, Gen Digital, Roblox

5. veebr 2026, 22:26 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9% -- Update

5. veebr 2026, 22:00 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9%

5. veebr 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

5. veebr 2026, 23:47 UTC

Market Talk

Nikkei May Fall After U.S. Tech Stock Drops -- Market Talk

5. veebr 2026, 23:43 UTC

Market Talk

Gold Falls on Spillover Impact From Cryptocurrencies' Selloff -- Market Talk

5. veebr 2026, 23:37 UTC

Market Talk

Glencore Shares Look Cheap After Failed Takeover Talks -- Market Talk

5. veebr 2026, 23:20 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 5th Update

5. veebr 2026, 23:11 UTC

Market Talk

Amazon CEO Confident in Return on $200B Investment -- Market Talk

5. veebr 2026, 23:09 UTC

Tulu

Naver 2025 Net KRW1.820T Vs. Net KRW1.932T >035420.SE

5. veebr 2026, 23:08 UTC

Tulu

Naver 2025 Oper Pft KRW2.208T Vs. Pft KRW1.979T >035420.SE

5. veebr 2026, 23:07 UTC

Tulu

Naver 2025 Rev KRW12.035T Vs. KRW10.738T >035420.SE

5. veebr 2026, 23:03 UTC

Market Talk

Tulu

REA's Update Looks Negative Despite A$200M Buyback -- Market Talk

5. veebr 2026, 23:03 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Bitcoin Booster's $12 Billion Loss Headlines Crypto's Worst Day Since 2022 Crash -- WSJ

5. veebr 2026, 23:00 UTC

Tulu

Naver 4Q Net Profit Missed FactSet-Compiled Consensus

5. veebr 2026, 23:00 UTC

Tulu

Naver 4Q Net KRW164.60B Vs. Net KRW514.00B >035420.SE

5. veebr 2026, 22:59 UTC

Tulu

Naver 4Q Oper Pft KRW610.60B Vs. Pft KRW542.00B >035420.SE

5. veebr 2026, 22:59 UTC

Tulu

Naver 4Q Rev KRW3.195T Vs. KRW2.886T >035420.SE

5. veebr 2026, 22:52 UTC

Tulu

Alphabet Stock Is Taking a Hit After Strong Earnings. Don't Panic. -- Barrons.com

5. veebr 2026, 22:45 UTC

Tulu

Amazon Stock Falls Sharply on Earnings. Spending Continues to Soar. -- Barrons.com

5. veebr 2026, 22:37 UTC

Market Talk

Woolworths's Profit Margin Likely Faces 2Q Squeeze -- Market Talk

5. veebr 2026, 22:11 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9% -- Update

5. veebr 2026, 22:03 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 4th Update

5. veebr 2026, 22:01 UTC

Tulu

Reddit Stock Jumps on Earnings. CFO Cites Modest AI Spending. -- Barrons.com

5. veebr 2026, 21:59 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

What's Next For Rio Tinto, Glencore After Deal Talks Fail? -- Market Talk

5. veebr 2026, 21:51 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Saylor's Strategy Posts $12 Billion Quarterly Loss on Bitcoin Selloff -- WSJ

5. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

5. veebr 2026, 21:49 UTC

Tulu

Why Google's Bad News Was Good News for Broadcom and Nvidia -- Barrons.com

5. veebr 2026, 21:45 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9%

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

147 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.